Single-arm pivotal trial initiated in Q4 2025 is dosing 15 females with Rett syndrome (ages 6 to <22) with a single intrathecal administration of TSHA-102 at 1×10^15 vg, using response rate—gain or regain of at least one of 28 natural history–defined developmental milestones—as the primary endpoint. A six-month interim readout from this pivotal REVEAL study may serve as the basis for a BLA. In parallel, a three-patient ASPIRE safety cohort (ages 2 to <4) will contribute a minimum of three months of safety data to the filing, with efficacy in ages 2 to <6 extrapolated from REVEAL to support a label for patients ≥2 years. The core development move is twofold: Taysha is advancing an intrathecally delivered AAV9 MECP2 gene therapy into a single-arm, open-label pivotal with a natural history–anchored endpoint, while securing FDA alignment to incorporate limited pediatric safety data and extrapolated efficacy to broaden the initial age range. Enrollment is underway across multiple sites, with dosing completion targeted in Q2 2026 for both REVEAL and ASPIRE. Longer-term safety and efficacy from REVEAL Part A are slated for the first half of 2026. The program benefits from Breakthrough Therapy and RMAT designations, positioning the six-month interim as a plausible accelerated-approval lever. Strategically, this is a speed-to-BLA plan that trades randomization and large sample sizes for regulatory-accepted external controls and milestone-based outcomes, consistent with FDA’s evolving stance in rare neurodevelopmental disorders. The choice of a binary, patient-as-own-control endpoint seeks to reduce variability while anchoring claims to concrete functional change. The extrapolation framework for younger patients compresses timelines and lowers enrollment burden, but it heightens the importance of a robust bridge—dose scaling for brain volume, age-related disease trajectory, and assayable consistency of effect. Underneath is a risk calculus around high-dose intrathecal AAV: IT delivery is intended to limit systemic exposure, and the miRARE element is designed to mitigate MECP2 overexpression risk, yet regulators will probe DRG pathology, immunogenicity, and durability as closely as efficacy. For sites, the operational load centers on intrathecal administration in pediatric and young adult females, sedation workflows, and intensive baseline and longitudinal functional assessments. The primary endpoint’s reliance on natural history–defined milestones pressures sponsors and CROs to standardize training, centralize adjudication, and control for rater bias and placebo-like caregiver expectations across centers. Recruitment feasibility seems manageable given the small N, but screening will be exacting to confirm plateau-stage status and align with dosing constraints. CROs and data partners will be critical in curating and harmonizing the natural history datasets that underpin both endpoint validity and any external comparisons, while manufacturing and release testing must stay locked to avoid comparability pitfalls mid-program. The near-term watchlist is clear: the six-month pivotal interim and the longer-term Part A update in 1H26 will need to show clinically meaningful, durable milestone gains with a clean intrathecal safety profile. Any signal drift across age bands will challenge the extrapolation rationale for the ≥2-year label. Post-approval commitments are likely if accelerated approval is pursued, increasing pressure on long-term follow-up infrastructure and registry readiness. Execution risk sits at the intersection of endpoint fidelity, AAV safety optics, and CMC stability; alignment on all three will determine whether the compressed path to BLA holds.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
